健脾益肝方对肝硬化大鼠AQP8的影响  

Effect of Jianpiyigan Prescription on the AQP8 of Cirrhotic Rats

作　　者：欧志穗[1] 刘友章[1] 陈裕杲[2] 

机构地区：[1]广州中医药大学第一附属医院二内科,广东广州510405 [2]广州中医药大学,广东广州510405

出　　处：《中华中医药学刊》2011年第7期1513-1515,I0002,共4页Chinese Archives of Traditional Chinese Medicine

基　　金：国家重点基础研究发展计划(973计划)资助项目(2005CB523502)

摘　　要：目的:观察健脾益肝方对肝硬化模型大鼠肝组织水通道蛋白AQP8表达的影响。方法:将90只Wist-ar大鼠随机分为空白对照组、模型组、健脾益肝方高、中、低剂量组及秋水仙碱组,运用CCL4法造肝硬化模型,并对肝脏组织作AQP8 PCR定量及Western Blotting检测。结果:模型组AQP8蛋白含量及平均光密度值和积分光密度值均很低,与空白组相比有极显著差异(P<0.01);经过治疗后健脾益肝方可以使AQP8蛋白含量及平均光密度值和积分光密度值均升高,其中疗效与中药使用剂量正相关,健脾益肝方低剂量组与模型组相比有显著差异(P<0.05),而健脾益肝方中剂量组及高剂量组与模型组相比具有极显著差异(P<0.01);秋水仙碱组与模型组比较没有显著差异(P>0.05)。结论:健脾益肝方对AQP8蛋白的升高作用是治疗肝硬化的靶点之一。Objective：The study aims to observe if JianPIYIGan prescription can improve the expression of the AQP8 of liver to experimental rats through TCM treatment.Method：The animal experiment consists of ninety Wistar rats which are divided into the blank group（group A）,the mould group and the group treating with JianPiYiGan prescription with high,medium and low dosages and the group treating with colchicines.Make the model group with CCL4,and check their livers＇ AQP8 PCR and Western Blotting.Results：The AQP8 quality of blank group has remarkable differences with the model group（P0.01）.The marks of AQP8 rise tremendously after treating by JianPiYiGan decoction,the effects among them in positive correlation with the dosage use of the TCM.There are significant difference between low dosage of JianPiYiGan decoction group and the blank group（P0.05）,and significant difference between high dosage group between medium dosage group（P0.01）.Minor difference exists between colchicines group and the blank group.（P0.05）.Conclusion：The therapeutic results that increase the quantity of AQP8 by JianPiYiGan prescription could be the new target of treating LC.

关 键 词：健脾益肝方 肝硬化 水通道蛋白AQP8 

分 类 号：R285.5[医药卫生—中药学]